Based on the company's latest reports for March 2026, the current 12-month EPS is -$1.94. Oruka Therapeutics's earnings per share in 2025 was reported at -$1.85, marking a rise from -$3.87 in 2024. In the quarterly report ending on Mar 31, 2026, ORKA's earnings per share amounted to -$0.48.
Oruka Therapeutics had an yealy earnings per share of -$1.85, showing a rise of 52.2% from -$3.87 recorded in 2024. The quarterly earnings per share for the period ending Mar 31, 2026, was -$0.48, showing a 20% decline compared to the same quarter last year. The trailing twelve months EPS for ORKA is -$1.94 as of March 2026. Oruka Therapeutics's full-year EPS for 2024 was -$3.87, a 12.8% rise compared to the previous year.
In the past 12 months, Oruka Therapeutics has recorded an earnings per share growth rate of -20% (YoY, quarterly).
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| UTHR UNITED THERAPEUTICS Corp | 18.69 | 14% | 23.5% | 20.9% |
| MDT Medtronic plc | 22.72 | 31% | -1.1% | 0.3% |
| CYTK Cytokinetics Inc | N/A | -24.3% | N/A | N/A |
| ORKA Oruka Therapeutics Inc. | N/A | 52.2% | N/A | N/A |
All data is based on quarterly TTM periods, unless otherwise specified.